Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
Epistemonikos ID: 116549adab702907120414c3ab40755ffdeb5fa7
First added on: May 13, 2024